Neurocrine Biosciences (NBIX) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neurocrine Biosciences (NBIX) has outperformed Zoetis (ZTS) over the past year, gaining 1.6% versus a loss of 49.1%. Over five years, NBIX leads with a +35.1% price change compared with -63.9% for ZTS. Zoetis is the larger company by market cap ($30.70 billion vs $14.43 billion), about 2.1 times the size, while Neurocrine Biosciences is growing revenue faster (+21.4% vs +2.3%).
On valuation, Zoetis trades at a lower forward P/E (11.4x vs 11.9x for Neurocrine Biosciences). Zoetis pays a dividend yielding 2.77%, while Neurocrine Biosciences does not currently pay one. Zoetis converts more of its revenue into profit, with a net margin of 28.2% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | ZTS |
|---|---|---|
| Share price | $141.93 | $74.31 |
| Market cap | $14.43B | $30.70B |
| 1-day change | +0.48% | +1.68% |
| YTD return | -0.41% | -41.92% |
| 1-year return | +1.56% | -49.07% |
| 5-year return | +35.12% | -63.86% |
| P/E ratio (TTM) | 20.81 | 12.22 |
| Forward P/E | 11.95 | 11.35 |
| EPS (TTM) | $6.82 | $6.08 |
| Dividend yield | 0.00% | 2.77% |
| Annual dividend | $0.00 | $2.06 |
| Revenue (latest FY) | $2.86B | $9.47B |
| Revenue growth (YoY) | +21.45% | +2.28% |
| Net income (latest FY) | $478.60M | $2.67B |
| Gross margin | 98.18% | 71.84% |
| Operating margin | 21.64% | — |
| Net margin | 16.73% | 28.23% |
| 52-week high | $186.12 | $148.30 |
| 52-week low | $122.14 | $68.77 |
| Distance from 52-week high | -23.74% | -49.90% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +46.05% | +29.20% |
| Average volume | 1.30M | 5.46M |
| Shares outstanding | 101.65M | 413.22M |
| Employees | 2,500 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Zoetis is about 2.1 times larger than Neurocrine Biosciences by market value ($30.70B vs $14.43B).
- NBIX has outperformed ZTS by 50.6 percentage points over the past year.
- Neurocrine Biosciences trades at a higher earnings multiple (20.8x vs 12.2x trailing P/E).
- Zoetis offers a meaningfully higher dividend yield (2.77% vs 0.00%).
- Zoetis is more profitable, keeping 28.2 cents of every revenue dollar as net income versus 16.7 cents for Neurocrine Biosciences.
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +2.28%).
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
NBIX vs ZTS FAQ
Which is bigger, Neurocrine Biosciences or Zoetis?
Zoetis (ZTS) is larger, with a market capitalization of $30.70B compared with $14.43B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, NBIX or ZTS?
NBIX returned +1.56% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NBIX or ZTS?
ZTS has the lower trailing P/E at 12.2, versus 20.8 for NBIX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Neurocrine Biosciences or Zoetis?
Zoetis pays a dividend yielding 2.77%, while Neurocrine Biosciences does not currently pay a regular dividend.
Are Neurocrine Biosciences and Zoetis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Neurocrine Biosciences and Biotechnology: Pharmaceutical Preparations for Zoetis.